MantroForce marketed five sexual-health and prostate products as unapproved new drugs, FDA says.
What happened
FDA reviewed MantroForce’s website in May 2026 and found five products marketed with claims to treat premature ejaculation, erectile dysfunction, and prostate or urinary symptoms. FDA determined the products are drugs and new drugs (drugs needing FDA approval because they are not generally recognized as safe and effective), with no approved applications. The letter quotes product webpage labeling as evidence of intended drug use.
What FDA found
The products are drugs because their labeling says they treat disease or affect body function.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are new drugs because they are not generally recognized as safe and effective for their labeled uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved application is in effect for any of the five products.
FD&C Act section 505(a), 21 U.S.C. 355(a)Selling or shipping these unapproved new drugs in U.S. commerce violates the law.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Website labeling shows the products are intended for drug uses.
21 CFR 201.128
What FDA wants
Send a written response to FDAAdvisory@fda.hhs.gov within 15 business days of receipt, including corrective steps, steps to prevent recurrence, and related documentation, with reference number 729021 in the subject line.
Who should pay attention
- online sellers of men’s sexual-health products
- marketplace and e-commerce compliance teams
- consumers buying prostate or erectile products online
This is a summary. Read the original letter on fda.gov.